Published in Neuroreport on April 24, 2006
NG2-glia as multipotent neural stem cells: fact or fantasy? Neuron (2011) 1.67
Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol (2009) 1.56
Inducible site-specific recombination in neural stem/progenitor cells. Genesis (2009) 1.31
Properties and fate of oligodendrocyte progenitor cells in the corpus callosum, motor cortex, and piriform cortex of the mouse. J Neurosci (2012) 1.24
Properties of doublecortin-(DCX)-expressing cells in the piriform cortex compared to the neurogenic dentate gyrus of adult mice. PLoS One (2011) 1.17
Doublecortin-expressing cells are present in layer II across the adult guinea pig cerebral cortex: partial colocalization with mature interneuron markers. Exp Neurol (2008) 1.15
Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol (2008) 1.03
Subventricular zone-derived, newly generated neurons populate several olfactory and limbic forebrain regions. Epilepsy Behav (2008) 0.95
Doublecortin-expressing cells persist in the associative cerebral cortex and amygdala in aged nonhuman primates. Front Neuroanat (2009) 0.95
Analysis of adult neurogenesis: evidence for a prominent "non-neurogenic" DCX-protein pool in rodent brain. PLoS One (2013) 0.90
Nestin-GFP transgene reveals neural precursor cells in adult skeletal muscle. PLoS One (2011) 0.89
Newborn cortical neurons: only for neonates? Trends Neurosci (2012) 0.88
Pulse labeling and long-term tracing of newborn neurons in the adult subgranular zone. Cell Res (2010) 0.87
Occurrence of new neurons in the piriform cortex. Front Neuroanat (2015) 0.86
New neurons from old beliefs in the adult piriform cortex? A Commentary on: "Occurrence of new neurons in the piriform cortex". Front Neuroanat (2015) 0.86
Noncanonical Sites of Adult Neurogenesis in the Mammalian Brain. Cold Spring Harb Perspect Biol (2015) 0.85
PSA-NCAM is Expressed in Immature, but not Recently Generated, Neurons in the Adult Cat Cerebral Cortex Layer II. Front Neurosci (2011) 0.83
Layer I as a putative neurogenic niche in young adult guinea pig cerebrum. Mol Cell Neurosci (2010) 0.82
Neurovascular signals suggest a propagation mechanism for endogenous stem cell activation along blood vessels. CNS Neurol Disord Drug Targets (2012) 0.79
Chronic lead exposure reduces doublecortin-expressing immature neurons in young adult guinea pig cerebral cortex. BMC Neurosci (2012) 0.78
Fast, potent pharmacological expansion of endogenous hes3+/sox2+ cells in the adult mouse and rat hippocampus. PLoS One (2012) 0.77
The (real) neurogenic/gliogenic potential of the postnatal and adult brain parenchyma. ISRN Neurosci (2013) 0.76
Neurogenesis within the adult hippocampus under physiological conditions and in depression. Neural Regen Res (2012) 0.76
Prenatal genesis of layer II doublecortin expressing neurons in neonatal and young adult guinea pig cerebral cortex. Front Neuroanat (2015) 0.75
Remodeling of the piriform cortex after lesion in adult rodents. Neuroreport (2014) 0.75
The neurobiology of antiepileptic drugs. Nat Rev Neurosci (2004) 3.24
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron (2003) 2.31
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2007) 1.97
Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci (2012) 1.97
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 1.89
Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: a review of current clinical experience. Epilepsia (2004) 1.87
Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia (2005) 1.86
Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther (2002) 1.60
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology (2011) 1.53
Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet (2010) 1.52
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 1.48
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol (2007) 1.40
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis (2006) 1.33
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci (2010) 1.29
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology (2006) 1.18
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther (2003) 1.14
Behavioral and cognitive alterations, spontaneous seizures, and neuropathology developing after a pilocarpine-induced status epilepticus in C57BL/6 mice. Exp Neurol (2009) 1.13
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology (2007) 1.11
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol (2010) 1.11
Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia (2002) 1.11
Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia (2006) 1.10
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp Neurol (2002) 1.08
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem (2005) 1.07
High resolution ultrasound in posterior interosseous nerve syndrome. Muscle Nerve (2013) 1.07
Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology (2006) 1.06
Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology (2010) 1.06
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther (2006) 1.05
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett (2002) 1.05
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology (2009) 1.03
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res (2008) 1.01
Pilocarpine vs. lithium-pilocarpine for induction of status epilepticus in mice: development of spontaneous seizures, behavioral alterations and neuronal damage. Eur J Pharmacol (2009) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. Hippocampus (2010) 0.98
The intrahippocampal kainate model of temporal lobe epilepsy revisited: epileptogenesis, behavioral and cognitive alterations, pharmacological response, and hippoccampal damage in epileptic rats. Epilepsy Res (2012) 0.97
Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia (2006) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia (2012) 0.95
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther (2009) 0.95
Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. Exp Neurol (2008) 0.95
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology (2009) 0.94
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol (2010) 0.93
Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem (2008) 0.93
Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res (2004) 0.91
The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci (2004) 0.91
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab (2012) 0.91
Issues related to development of antiepileptogenic therapies. Epilepsia (2013) 0.91
Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics (2014) 0.91
Drug resistance in epilepsy: why is a simple explanation not enough? Epilepsia (2007) 0.90
Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis (2008) 0.89
Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology (2010) 0.89
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia (2004) 0.88
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res (2004) 0.88
Effect of aging on neurogenesis in the canine brain. Aging Cell (2008) 0.88
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res (2002) 0.88
The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs (2014) 0.88
Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res (2003) 0.87
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia (2002) 0.87
Marked strain and substrain differences in induction of status epilepticus and subsequent development of neurodegeneration, epilepsy, and behavioral alterations in rats. [corrected]. Epilepsy Res (2011) 0.87
Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis (2005) 0.87
Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. Epilepsia (2004) 0.86
Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy. Epilepsia (2007) 0.86
Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos (2013) 0.86
New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr (2009) 0.86
Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia (2002) 0.86
Animal models of limbic epilepsies: what can they tell us? Brain Pathol (2002) 0.86
Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models. Neurotoxicology (2011) 0.86
Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia (2008) 0.86
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol (2014) 0.85
Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem (2011) 0.85
In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia (2009) 0.85
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84
Subregional changes in discharge rate, pattern, and drug sensitivity of putative GABAergic nigral neurons in the kindling model of epilepsy. Eur J Neurosci (2004) 0.84